Neuralace Medical

Executive Summary

Neuralace Medical is a San Diego-based medical device company developing Axon Therapy®, a non-invasive magnetic Peripheral Nerve Stimulation (mPNS) platform that received FDA clearance for the treatment of chronic neuropathic pain. Founded in 2019, the company's drug-free, needle-free approach aims to recondition the central nervous system to provide long-term pain relief. With an FDA-cleared product already on the market, Neuralace is positioned to capture a significant share of the growing neuromodulation market, which is expanding as patients and providers seek non-opioid alternatives for chronic pain management. Looking ahead, the company's growth trajectory hinges on expanding its label to additional pain indications and scaling commercial adoption. Key upcoming catalysts include the initiation of a pivotal clinical trial for migraine or post-surgical pain, which could open a much larger addressable market. Additionally, a strategic distribution partnership with a major medical device player would validate the technology and accelerate revenue. Finally, a Series B financing round is likely to support these expansion efforts. With its innovative platform and clear regulatory pathway, Neuralace represents a compelling opportunity in neuromodulation.

Upcoming Catalysts (preview)

• Q1 2027Initiation of pivotal trial for new indication (e.g., migraine)65% success
• Q4 2026Strategic distribution partnership50% success
• H2 2026Series B financing round75% success